Ipsen SA (IPSEF) reports robust financial performance with a 9.9% sales increase and strategic pipeline developments, despite ...

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all ...

Q4 2024 Management View CEO David Loew emphasized Ipsen’s sustained growth in 2024, with total sales increasing by 9.9%. He highlighted the strong performance of the ex-Somatuline portfolio, which ...

A former executive at French drugmaker Ipsen was sentenced on Thursday to two months in a U.S. prison for illegally trading ...

Shares of Ipsen (EPA:IPN) dropped 2.7% as the market reacted to the company's mixed fourth-quarter results. Despite reporting ...

UBS analyst Xian Deng maintained a Buy rating on Ipsen (0MH6 – Research Report) today and set a price target of €145.00. The company’s shares ...

In a report released on February 11, Justine Telliez from Kepler Capital maintained a Hold rating on Ipsen (0MH6 – Research Report), with a ...

Ipsen is a growing biopharma company that combines a dynamic, biotech mindset with the resources that come from having 5,400 employees and a direct presence in more than 30 countries. This ...

French drugmaker Ipsen today released final results from the Phase III CheckMate -9ER trial of Cabometyx (cabozantinib) in ...

Ipsen has suffered a setback in its marathon effort to bring palovarotene to market for ultra rare disease fibrodysplasia ossificans progressiva (FOP), after EU advisors recommended against approval.

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with ...

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...